What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The OPTIMA trial showed a significant reduction in new CT-detected HO lesions with garetosmab compared to placebo, with rate ratios of 0.06 and 0.10. However, the trial had a small sample size and wide confidence intervals, limiting the certainty of the magnitude of effect.
Does the economic case hold at the expected price? — Cost effectiveness
No cost-utility analysis, ICER, or economic model was identified for garetosmab, making cost-effectiveness not assessable.
Is there quality-of-life evidence payers weigh? — Quality of life
While several HRQoL instruments were used, no significant patient-reported flare-up differences were found, and no utility or functional results were publicly available, limiting the assessment of HRQoL benefits.
Does the safety profile hold up for payers? — Safety and Adverse Effects
OPTIMA reported common adverse events such as abscesses and acne, with no deaths through week 56. However, long-term safety remains uncertain due to the small exposed population and potential risks like embryo-fetal toxicity.
Was the drug compared against what payers expect? — Comparator Selection
Placebo was an acceptable comparator at trial initiation, but the relevance has decreased with the availability of other treatments like palovarotene. No direct comparison with active treatments was made.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population was representative of young adults with classic FOP, but lacked diversity and did not include children or older adults, limiting generalizability.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
The treatment fits into existing pathways with minor adjustments needed for infusion administration and monitoring, which are manageable within current healthcare settings.
Are the wider system costs understood? — Resource Use and Cost Implications
No budget-impact or resource-use data were presented, making it not assessable.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The OPTIMA trial was a well-designed phase 3 RCT with high retention and prespecified endpoints, but had limitations in sample size and lack of active control.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
High uncertainty remains due to small lesion counts, wide confidence intervals, and lack of long-term functional outcomes. The direction of effect is consistent, but magnitude and clinical translation are uncertain.